See also separate entry for trifluridine.
- TRADE NAMES: Lonsurf (Monarch); TAS-102
- INDICATIONS: Metastatic colorectal cancer in patients who have been previously treated with fluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Thymidine phosphorylase inhibitor, Thymidine-based nucleoside analogue
- HALF-LIFE: 2 hours
- FDA APPROVAL DATE: 09/22/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Can cause fetal harm
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of Trifluridine & Tipiracil in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/18/2024
